Formulation: A crystalline solid

Purity: ≥95%

• Camboginol
• Guttiferone F

Formulation: A crystalline solid

Purity: ≥97%

• Ephdine

• Histone Acetyltransferase

Formulation: A crystalline solid

Purity: ≥98% (mixture of isomers)

Formulation: 50 mM HEPES, pH 8, with 150 mM NaCl, 1 mM EDTA, and 20% glycerol

Purity: ≥80% estimated by SDS-PAGE

• HAT
• p300/(CREB binding protein) Associated Factor

Formulation: A lyophilized powder

Purity: ≥95%

• Click Tag™ 4-pentynoyl-CoA

Formulation: A crystalline solid

Purity: ≥98%

• 6-pentadecyl Salicylic Acid

Formulation: A crystalline solid

Purity: ≥98% (mixture of isomers)

Formulation: A crystalline solid

Purity: ≥95%

Formulation: 50 mM Tris, pH 8.0, with 150 mM sodium chloride and 20% glycerol

Purity: ≥50% estimated by SDS-PAGE

• General control of amino acid synthesis protein 5-like 2
• KAT2A
• Lysine acetyltransferase 2A
• STAF97

Formulation: 50 mM Tris-HCl, pH 7.5, with 300 mM sodium chloride and 10% glycerol

Purity: ≥50%

• cPLA(2) Interacting Protein
• Esa1
• Histone acetyltransferase KAT5
• HIV-1 Tat Interacting Protein 60 kDa
• Hs.6364
• HTATIP
• KAT5
• PLIP

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A lyophilized peptide

Purity: ≥95%

• H3 Peptide

Formulation: A crystalline solid

Purity: ≥95%

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A solid

Purity: ≥98%

• CBP-IN-1

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A crystalline solid

Purity: ≥95%

Formulation: A crystalline solid

Purity: ≥98%

• L-45

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A crystalline solid

Purity: ≥98%

• p300/CBP Inhibitor VI
• NSC 764414

Formulation: A crystalline solid

Purity: ≥98%

Formulation: A solid

Purity: ≥98%